Hvis gentagne målinger af koagulopati (inklusiv trombocyttal) indikerer svær eller forværret koagulopati, skal risikoen ved fortsat infusion afvejes mod den forventede fordel.
If sequential measures of coagulopathy (including platelet count) indicate severe or worsening coagulopathy, the risk of continuing the infusion should be weighed against the expected benefit.